- $1.20tn
- $1.24tn
- $65.18bn
Street View: Next-generation drugs bolster Lilly's growth outlook
US STOCKS-Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
US STOCKS-Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
US STOCKS-Wall Street slides as Alphabet revenue miss revives AI capex jitters
US STOCKS ON THE MOVE-Wesco, Mobileye, Glaukos
Quotes: Lilly's obesity drug strength fuels record rally, Wall Street optimism
U.S. STOCKS ON THE MOVE-ADT, Equinix, Cognizant
Live Markets: Thursday data "accumulation": GDP, PCE, jobless claims
Live Markets: Alphabet drags Nasdaq as healthcare, housing, banks shine
Eli Lilly gains after lifting annual revenue view
Eli Lilly and Company reports results for the quarter ended September 30 - Earnings Summary
U.S. STOCKS ON THE MOVE-Alphabet, Ford, DoorDash
Live Markets: AI spending concerns overshadow steady economic data
U.S. STOCKS ON THE MOVE-Microsoft, L3Harris, Eli Lilly
Eli Lilly rises after lifting annual revenue view
US drugmaker Eli Lilly beats Q3 revenue estimates on product demand, lifts FY outlook
Eli Lilly lifts revenue outlook as weight-loss shot demand soars, shares jump (updated)
Brief: Lilly Q3 Adjusted EPS USD 7.48 Vs. IBES Estimate USD 6.49
Biogen tops quarterly estimates on rare-disease drug strength (updated)